Glucagon-like-1 receptor agonists and sodium/glucose cotransporter-2 inhibitors combination—are we exploiting their full potential in a real life setting?

doi:10.4239/wjd.v11.i11.540

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 11, Issue 11

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (5468)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-6) series.

Item

Count

PDF

370

WORD

211

HTML

2651

Figures (1-1)

222

Tables (1-6)

239

Sum=3693

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

550

Download

1225

Sum=1775

Nov 15, 2020 (publication date) through Sep 22, 2024

Times Cited of This Article

Times Cited (4)

Journal Information of This Article

Publication Name

World Journal of Diabetes

ISSN

1948-9358

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Observational Study

World J Diabetes. Nov 15, 2020; 11(11): 540-552
Published online Nov 15, 2020. doi: 10.4239/wjd.v11.i11.540

Table 3 Difference in antihyperglycemic therapy between three therapy groups

	Therapy group
	SGLT-2i, n (%)	GLP-1RA, n (%)	Simultaneous, n (%)
Insulin	11 (32.4)	28 (45.2)	11 (26.2)
Metformin	32 (94.1)	53 (85.5)	33 (78.6)
SU	4 (11.8)	12 (19.4)	6 (14.3)
Other OAD	3 (8.8)	10 (16.1)	8 (19.0)

GLP-1: Glucagon-like-poylpeptide-1 receptor agonist; OAD: Oral antihyperglycemic drugs; SGLT-2i: Sodium/glucose cotransporter-2 inhibitors; SU: Sulphonylurea.

Citation: Cigrovski Berkovic M, Bilic-Curcic I, Bozek T, Herman Mahecic D, Klobucar Majanovic S, Canecki-Varzic S, Andric J, Marusic S, Mrzljak A. Glucagon-like-1 receptor agonists and sodium/glucose cotransporter-2 inhibitors combination—are we exploiting their full potential in a real life setting? World J Diabetes 2020; 11(11): 540-552
URL: https://www.wjgnet.com/1948-9358/full/v11/i11/540.htm
DOI: https://dx.doi.org/10.4239/wjd.v11.i11.540